NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis $6.15 -0.17 (-2.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.13▼$6.4650-Day Range$5.09▼$10.4052-Week Range$4.10▼$11.30Volume11,177 shsAverage Volume69,596 shsMarket Capitalization$60.89 millionP/E RatioN/ADividend YieldN/APrice Target$43.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Hookipa Pharma alerts: Email Address Hookipa Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside603.3% Upside$43.25 Price TargetShort InterestHealthy1.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.45) to ($7.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 starsMedical Sector579th out of 936 stocksPharmaceutical Preparations Industry264th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHookipa Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Hookipa Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.23% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently increased by 47.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOOK. Previous Next 1.9 News and Social Media Coverage News SentimentHookipa Pharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Hookipa Pharma this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for HOOK on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hookipa Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to decrease in the coming year, from ($3.45) to ($7.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hookipa Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Hookipa Pharma Stock (NASDAQ:HOOK)HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More HOOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOOK Stock News HeadlinesJuly 26 at 5:45 AM | markets.businessinsider.comOptimistic Outlook for Hookipa Pharma’s Oncology Pipeline Prompts Buy RatingJuly 23 at 10:04 AM | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 22, 2024 | globenewswire.comHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200July 8, 2024 | globenewswire.comHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock SplitJuly 1, 2024 | globenewswire.comHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIVJune 4, 2024 | globenewswire.comHOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual MeetingMay 30, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual MeetingJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma Amid Positive HB-200 Vaccine Trials and Robust Financial PositionMay 23, 2024 | globenewswire.comHOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingMay 21, 2024 | markets.businessinsider.comDeep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)May 16, 2024 | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 11, 2024 | finance.yahoo.comHOOKIPA Pharma First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | globenewswire.comHOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 27, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 26, 2024 | markets.businessinsider.comBreaking Down HOOKIPA Pharma: 4 Analysts Share Their ViewsSee More Headlines Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$50.00 High Stock Price Target$60.00 Low Stock Price Target$40.00 Potential Upside/Downside+709.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net Margins-88.73% Pretax Margin-88.43% Return on Equity-33.33% Return on Assets-20.22% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual Sales$20.13 million Price / Sales3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book0.68Miscellaneous Outstanding Shares9,900,000Free Float9,568,000Market Cap$61.18 million OptionableOptionable Beta0.81 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joern Aldag (Age 60)Pres, CEO & Director Mr. Daniel Pinschewer (Age 44)Founder & Chief Scientific Officer Dr. Reinhard Kandera (Age 50)CFO & Director Mr. Anders Lilja Ph.D. (Age 46)Sr. VP of Technical Devel. Mrs. Nina WaibelCommunications & Investor Relations Mang.Key CompetitorsGritstone bioNASDAQ:GRTSNeon TherapeuticsNASDAQ:NTGNImmutepNASDAQ:IMMPGossamer BioNASDAQ:GOSSAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 43,021 shares on 5/20/2024Ownership: 0.043%Acadian Asset Management LLCBought 407,532 shares on 5/10/2024Ownership: 0.892%Reinhard KanderaBought 700 shares on 8/21/2023Total: $5,040.00 ($7.20/share)Reinhard KanderaBought 800 shares on 8/16/2023Total: $5,680.00 ($7.10/share)View All Insider TransactionsView All Institutional Transactions HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? Hookipa Pharma's stock was trading at $8.10 at the beginning of the year. Since then, HOOK shares have decreased by 24.1% and is now trading at $6.15. View the best growth stocks for 2024 here. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) issued its quarterly earnings data on Thursday, May, 9th. The company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of ($1.20) by $2.40. The business had revenue of $36.60 million for the quarter, compared to the consensus estimate of $3.20 million. Hookipa Pharma had a negative net margin of 88.73% and a negative trailing twelve-month return on equity of 33.33%. When did Hookipa Pharma's stock split? Shares of Hookipa Pharma reverse split before market open on Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Hookipa Pharma IPO? Hookipa Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC) and Alector (ALEC). This page (NASDAQ:HOOK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts